ClinicalTrials.gg
CompletedNCT00628862OCEANUpdated Oct 25, 2012Results posted

Evaluation of Efficacy and Safety of Formoterol in Patients With COPD Compared With Placebo in Patients in Japan, EU

A Phase 3 interventional study of Formoterol Turbuhaler® 4.5mg and Formoterol Turbuhaler® 9 mg in Chronic Obstructive Pulmonary Disease, sponsored by AstraZeneca. Completed at 48 sites in 5 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2012-10-25.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
613
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive — 3 open to participants now, 3 under way, 1 of them phase 3. formoterol · Pulmonary Disease, Chronic Obstructive.

Enrollment
26th of 89
613 · median 120
Started
2007
with 4 others
Phase 3
40 of 89
1 open now
Registered
20th of 89
by date
Lead sponsor
20 of 89
AstraZeneca

Among the 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive, this one is the 26th largest by enrollment, is one of 5 that started in 2007, is one of 40 in phase 3, and was the 20th registered.

Pulmonary Disease, Chronic Obstructive

5,527 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

3 of the 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About formoterol

formoterol: first FDA approval 2001 (FORADIL), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

The purpose of this study is to show the efficacy and safety of formoterol for the maintenance treatment of patients with COPD compared with placebo in patients in Japan and in European countries during 12 weeks.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • Chronic Obstructive Pulmonary Disease
  • COPD
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females aged above 40 with a clinical diagnosis of and current COPD symptoms
  • Current or previous smoker with a smoking history of 10 or more pack years
  • Lung function parameters: /FVC \< 70%, post-bronchodilator and post-bronchodilator FEV1 \< 80% of predicted normal value

Exclusion criteria

Exclusion Criteria:

  • History and/or current clinical diagnosis of asthma or atopic diseases such as allergic rhinitis
  • Use of inhaled glucocorticosteroids within 4 weeks prior to Visit 2
  • Any relevant cardiovascular disorder as judged by the investigator or any current respiratory tract disorder other than .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
613 participants (actual)

Study arms

  • Experimental
    F 4.5 bid

    Formoterol 4.5 ug twice daily (bid)

    Drug: Formoterol Turbuhaler® 4.5mg

  • Experimental
    F 9.0 bid

    Formoterol 9.0 ug bid

    Drug: Formoterol Turbuhaler® 9 mg

  • Placebo comparator
    PBO

    Placebo

    Drug: Turbuhaler® placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Forced Expiratory Volume in 1 Second (FEV1; L) 60 Minutes Post-dose

    FEV1 (expressed as litres \[L\]) is a spirometric measure of lung function. FEV1 was measured 60 minutes after administration of study drug. The results are expressed as a percentage in relation to the baseline value.

    Time frame: from baseline up to 12 weeks

Secondary outcomes

  1. Forced Vital Capacity (FVC) 60 Minutes Post-dose

    Forced Vital Capacity (FVC) is a spirometric measure of lung function. FVC was measured 60 minutes after administration of study drug. The results are expressed as a percentage in relation to the baseline value

    Time frame: from baseline up to 12 weeks

  2. FEV1 Pre-dose

    Lung function (FEV1) was measured before administrations of the study drug (pre-dose). The results are expressed as a percentage of mean FEV1 over visists 4-6 in relation to the baseline (visit 3) value

    Time frame: baseline at week 0 and pre-dose at weeks 4, 8 and 12

  3. FVC Pre-dose

    Lung function (FVC) was measured before administrations of the study drug (pre-dose). The results are expressed as a percentage of mean FEV1 over visists 4-6 in relation to the baseline (visit 3) value

    Time frame: baseline at week 0 and pre-dose at weeks 4, 8 and 12

  4. FEV1 5 Minutes Post-dose

    Lung function (FEV1) was measured 5 minutes after the first dose of study drug. The results are expressed as a percentage in relation to the baseline value

    Time frame: baseline and 5 minutes anter first dose

  5. FVC 5 Minutes Post-dose

    Lung function (FVC) was measured 5 minutes after the first dose of study drug, The results are expressed as a percentage in relation to the baseline value

    Time frame: baseline and 5 minutes anter first dose

  6. Change in Peak Expiratory Flow (PEF), Morning

    Patients were asked to measure and record lung function (peak expiratory flow \[PEF\] measured in the morning). Average values over the last 10 days of the run-in period and the whole treatment period were calculated. The results are expressed as the change from the run-in period average value

    Time frame: run-in period and 12 week

  7. Change in Peak Expiratory Flow (PEF), Evening

    Patients were asked to measure and record lung function (peak expiratory flow \[PEF\] measured in the evening). Average values over the last 10 days of the run-in period and the whole treatment period were calculated. The results are expressed as the change from the run-in period average value

    Time frame: run-in period and 12 week

  8. Change in Night-time Awakenings Due to Symptoms

    Patients were asked to record the night-time awakenings due to symptoms (scored from 0-4 with 4 being the most severe). Period averages over the last 10 days of the run-in period and the whole treatment period were calculated. The results are expressed as the change from the run-in period average value

    Time frame: run-in period up to 12 weeks

  9. Breathlessness

    Patients were asked to record breathlessness (scored from 0-4 with 4 being the most severe). Period averages over the last 10 days of the run-in period and the whole treatment period were calculated. The results are expressed as the change from the run-in period average value

    Time frame: run-in period up to 12 weeks

  10. Cough

    Patients were asked to record cough (scored from 0-4 with 4 being the most severe). Period averages over the last 10 days of the run-in period and the whole treatment period were calculated. The results are expressed as the change from the run-in period average value

    Time frame: run-in period up to 12 weeks

  11. Use of Reliever Medication

    Patients were asked to record reliever medication use. Period averages over the last 10 days of the run-in period and the whole treatment period were calculated. The results are expressed as the change from the run-in period average value

    Time frame: 12 weeks (end of run-in to last visit)

  12. St George's Respiratory Questionnaire (SGRQ)

    Patients were asked to complete the St George's Respiratory Questionnaire (SGRQ). Subscale symptom score ranges from 0 to 100% and measures the effect of respiratory symptoms, frequency, and severity on quality of life. A score of 0 indicates the best possible status. Results are expressed as the change from baseline score with a decrease in score indicating improvement.

    Time frame: 12 weeks (end of run-in to last visit)

07

Results

Posted Oct 25, 2012

Participant flow

Outpatients, male or female aged ≥ 40 years with moderate to severe chronic obstructive pulmonary disease (COPD). 766 subjects enrolled; 153 excluded: 96 for incorrect enrollment, 17 for adverse events, 32 for voluntary discontinuation, 1 for non-compliance with protocol, 7 for other reasons. 613 were randomised.

Participant flow — Overall Study
MilestoneFormoterol 4.5 BidFormoterol 9.0 BidPlacebo
Started206199208
Completed195182186
Not completed111722
Withdrew: Adverse event6810
Withdrew: Withdrawal by subject4611
Withdrew: Lost to follow-up021
Withdrew: Protocol violation100
Withdrew: Copd exacerbation010

Outcome measures

PrimaryForced Expiratory Volume in 1 Second (FEV1; L) 60 Minutes Post-dose

FEV1 (expressed as litres \[L\]) is a spirometric measure of lung function. FEV1 was measured 60 minutes after administration of study drug. The results are expressed as a percentage in relation to the baseline value.

Time frame:
from baseline up to 12 weeks
Reported as:
Geometric mean · percent of baseline
Forced Expiratory Volume in 1 Second (FEV1; L) 60 Minutes Post-dose
percent of baselineFormoterol 4.5 BidFormoterol 9.0 BidPlacebo
Forced Expiratory Volume in 1 Second (FEV1; L) 60 Minutes Post-dose112.9 (75.1 to 177.0)113.36 (66.2 to 184.0)101.28 (58.3 to 189.1)
SecondaryForced Vital Capacity (FVC) 60 Minutes Post-dose

Forced Vital Capacity (FVC) is a spirometric measure of lung function. FVC was measured 60 minutes after administration of study drug. The results are expressed as a percentage in relation to the baseline value

Time frame:
from baseline up to 12 weeks
Reported as:
Geometric mean · percent of baseline
Forced Vital Capacity (FVC) 60 Minutes Post-dose
percent of baselineFormoterol 4.5 BidFormoterol 9.0 BidPlacebo
Forced Vital Capacity (FVC) 60 Minutes Post-dose109.73 (81.2 to 162.0)109.92 (83.2 to 200.9)102.11 (71.2 to 212.7)
SecondaryFEV1 Pre-dose

Lung function (FEV1) was measured before administrations of the study drug (pre-dose). The results are expressed as a percentage of mean FEV1 over visists 4-6 in relation to the baseline (visit 3) value

Time frame:
baseline at week 0 and pre-dose at weeks 4, 8 and 12
Reported as:
Geometric mean · percent of baseline
FEV1 Pre-dose
percent of baselineFormoterol 4.5 BidFormoterol 9.0 BidPlacebo
FEV1 Pre-dose104.54 (73.3 to 175.0)104.65 (71.0 to 172.6)99.77 (56.5 to 183.6)
SecondaryFVC Pre-dose

Lung function (FVC) was measured before administrations of the study drug (pre-dose). The results are expressed as a percentage of mean FEV1 over visists 4-6 in relation to the baseline (visit 3) value

Time frame:
baseline at week 0 and pre-dose at weeks 4, 8 and 12
Reported as:
Geometric mean · percent of baseline
FVC Pre-dose
percent of baselineFormoterol 4.5 BidFormoterol 9.0 BidPlacebo
FVC Pre-dose103.62 (77.7 to 149.8)103.36 (68.9 to 162.7)100.73 (70.8 to 211.9)
SecondaryFEV1 5 Minutes Post-dose

Lung function (FEV1) was measured 5 minutes after the first dose of study drug. The results are expressed as a percentage in relation to the baseline value

Time frame:
baseline and 5 minutes anter first dose
Reported as:
Geometric mean · percent of baseline
FEV1 5 Minutes Post-dose
percent of baselineFormoterol 4.5 BidFormoterol 9.0 BidPlacebo
FEV1 5 Minutes Post-dose110.16 (65.6 to 156.5)110.24 (80.6 to 155.1)101.25 (79.4 to 121.6)
SecondaryFVC 5 Minutes Post-dose

Lung function (FVC) was measured 5 minutes after the first dose of study drug, The results are expressed as a percentage in relation to the baseline value

Time frame:
baseline and 5 minutes anter first dose
Reported as:
Geometric mean · percent of baseline
FVC 5 Minutes Post-dose
percent of baselineFormoterol 4.5 BidFormoterol 9.0 BidPlacebo
FVC 5 Minutes Post-dose108.50 (89.9 to 143.2)108.88 (81.5 to 153.4)101.59 (84.3 to 124.7)
SecondaryChange in Peak Expiratory Flow (PEF), Morning

Patients were asked to measure and record lung function (peak expiratory flow \[PEF\] measured in the morning). Average values over the last 10 days of the run-in period and the whole treatment period were calculated. The results are expressed as the change from the run-in period average value

Time frame:
run-in period and 12 week
Reported as:
Mean · L/min
Change in Peak Expiratory Flow (PEF), Morning
L/minFormoterol 4.5 BidFormoterol 9.0 BidPlacebo
Change in Peak Expiratory Flow (PEF), Morning16.27 ± 27.9018.34 ± 26.193.60 ± 27.08
SecondaryChange in Peak Expiratory Flow (PEF), Evening

Patients were asked to measure and record lung function (peak expiratory flow \[PEF\] measured in the evening). Average values over the last 10 days of the run-in period and the whole treatment period were calculated. The results are expressed as the change from the run-in period average value

Time frame:
run-in period and 12 week
Reported as:
Mean · L/min
Change in Peak Expiratory Flow (PEF), Evening
L/minFormoterol 4.5 BidFormoterol 9.0 BidPlacebo
Change in Peak Expiratory Flow (PEF), Evening13.15 ± 27.5215.76 ± 25.222.36 ± 26.43
SecondaryChange in Night-time Awakenings Due to Symptoms

Patients were asked to record the night-time awakenings due to symptoms (scored from 0-4 with 4 being the most severe). Period averages over the last 10 days of the run-in period and the whole treatment period were calculated. The results are expressed as the change from the run-in period average value

Time frame:
run-in period up to 12 weeks
Reported as:
Mean · scores on a scale per day
Change in Night-time Awakenings Due to Symptoms
scores on a scale per dayFormoterol 4.5 BidFormoterol 9.0 BidPlacebo
Change in Night-time Awakenings Due to Symptoms-0.1318 ± 0.4791-0.1748 ± 0.5517-0.0466 ± 0.4900
SecondaryBreathlessness

Patients were asked to record breathlessness (scored from 0-4 with 4 being the most severe). Period averages over the last 10 days of the run-in period and the whole treatment period were calculated. The results are expressed as the change from the run-in period average value

Time frame:
run-in period up to 12 weeks
Reported as:
Mean · scores on a scale per day
Breathlessness
scores on a scale per dayFormoterol 4.5 BidFormoterol 9.0 BidPlacebo
Breathlessness-0.4068 ± 0.6193-0.4531 ± 0.5511-0.2626 ± 0.5899
SecondaryCough

Patients were asked to record cough (scored from 0-4 with 4 being the most severe). Period averages over the last 10 days of the run-in period and the whole treatment period were calculated. The results are expressed as the change from the run-in period average value

Time frame:
run-in period up to 12 weeks
Reported as:
Mean · scores on a scale per day
Cough
scores on a scale per dayFormoterol 4.5 BidFormoterol 9.0 BidPlacebo
Cough-0.3250 ± 0.6424-0.4088 ± 0.6374-0.2016 ± 0.6233
SecondaryUse of Reliever Medication

Patients were asked to record reliever medication use. Period averages over the last 10 days of the run-in period and the whole treatment period were calculated. The results are expressed as the change from the run-in period average value

Time frame:
12 weeks (end of run-in to last visit)
Reported as:
Mean · medication doses per day
Use of Reliever Medication
medication doses per dayFormoterol 4.5 BidFormoterol 9.0 BidPlacebo
Use of Reliever Medication-0.60 ± 1.47-0.97 ± 1.88-0.23 ± 1.25
SecondarySt George's Respiratory Questionnaire (SGRQ)

Patients were asked to complete the St George's Respiratory Questionnaire (SGRQ). Subscale symptom score ranges from 0 to 100% and measures the effect of respiratory symptoms, frequency, and severity on quality of life. A score of 0 indicates the best possible status. Results are expressed as the change from baseline score with a decrease in score indicating improvement.

Time frame:
12 weeks (end of run-in to last visit)
Reported as:
Mean · Scores on a scale
St George's Respiratory Questionnaire (SGRQ)
Scores on a scaleFormoterol 4.5 BidFormoterol 9.0 BidPlacebo
St George's Respiratory Questionnaire (SGRQ)-5.46 ± 12.12-6.38 ± 10.77-2.02 ± 12.98

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Formoterol 4.5 Bid—6/206 (2.9%)33/206 (16%)
Formoterol 9.0 Bid—7/199 (3.5%)31/199 (15.6%)
Placebo—4/208 (1.9%)31/208 (14.9%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventFormoterol 4.5 BidFormoterol 9.0 BidPlacebo
PneumoniaInfections and infestations2/2062/1990/208
Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders0/2061/1992/208
Lobar PneumoniaInfections and infestations0/2061/1990/208
Gastric CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2061/1990/208
Hypoglycaemic UnconsciousnessMetabolism and nutrition disorders0/2061/1990/208
Angina PectorisCardiac disorders0/2061/1990/208
DeathGeneral disorders1/2060/1990/208
Prostate CanerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2060/1990/208
Diabetes MellitusMetabolism and nutrition disorders1/2060/1990/208
Cardiopulmonary FailureCardiac disorders1/2060/1990/208
Most frequent other events
Most frequent other events
EventFormoterol 4.5 BidFormoterol 9.0 BidPlacebo
NasopharyngitisInfections and infestations24/20625/19920/208
Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders10/2067/19915/208

Baseline characteristics

Age Continuous
Age Continuous(Years)Formoterol 4.5 BidFormoterol 9.0 BidPlaceboTotal
Mean66.7 ± 9.467.2 ± 9.266.3 ± 9.766.75 ± 9.4
Sex: Female, Male
Sex: Female, Male(Participants)Formoterol 4.5 BidFormoterol 9.0 BidPlaceboTotal
Female23292274
Male183170186539
08

Study locations

48 sites
  • Research Site
    Gabrovo, Bulgaria
  • Research Site
    Lovech, Bulgaria
  • Research Site
    Pleven, Bulgaria
  • Research Site
    Russe, Bulgaria
  • Research Site
    Sofia, Bulgaria
  • Research Site
    Stara Zagora, Bulgaria
  • Research Site
    Troyan, Bulgaria
  • Research Site
    Varna, Bulgaria
  • Research Site
    Nagoya, Aichi, Japan
  • Research Site
    Seto, Aichi, Japan
  • Research Site
    Noda, Chiba, Japan
  • Research Site
    Touon, Ehime, Japan
  • Research Site
    Yanagawa, Fukuoka, Japan
  • Research Site
    ORA, Gunma, Japan
  • Research Site
    OTA, Gunma, Japan
  • Research Site
    Asahikawa, Hokkaido, Japan
  • Research Site
    Chitose, Hokkaido, Japan
  • Research Site
    Obihiro, Hokkaido, Japan
  • Research Site
    Sapporo, Hokkaido, Japan
  • Research Site
    Tomakomai, Hokkaido, Japan
  • Research Site
    Yabu, Hyogo, Japan
  • Research Site
    Naka-gun, Ibaraki, Japan
  • Research Site
    Morioka, Iwate, Japan
  • Research Site
    Kawasaki, Kangawa, Japan
  • Research Site
    Sendai, Miyagi, Japan
  • Research Site
    Katano, Osaka, Japan
  • Research Site
    Kishiwada, Osaka, Japan
  • Research Site
    Takatsuiki, Osaka, Japan
  • Research Site
    Chiyoda, Tokyo, Japan
  • Research Site
    UBE, Yamaguchi, Japan
  • Research Site
    Hiroshima, Japan
  • Research Site
    Kagoshima, Japan
  • Research Site
    Kochi, Japan
  • Research Site
    Kyoto, Japan
  • Research Site
    Osaka, Japan
  • Research Site
    Wakayama, Japan
  • Research Site
    Deva, Hunedoara, Romania
  • Research Site
    Bucharest, Romania
  • Research Site
    Bucuresti, Romania
  • Research Site
    Constanta, Romania
  • Research Site
    Iasi, Romania
  • Research Site
    Kazan, Russian Federation
  • Research Site
    Moscow, Russian Federation
  • Research Site
    St. Petersburg, Russian Federation
  • Research Site
    Dnipropetrovsk, Ukraine
  • Research Site
    Donetsk, Ukraine
  • Research Site
    Kharkiv, Ukraine
  • Research Site
    Kyiv, Ukraine
09

References and documents

Publications

  • Bogdan MA, Aizawa H, Fukuchi Y, Mishima M, Nishimura M, Ichinose M. Efficacy and safety of inhaled formoterol 4.5 and 9 mug twice daily in Japanese and European COPD patients: phase III study results. BMC Pulm Med. 2011 Nov 15;11:51. doi: 10.1186/1471-2466-11-51. PubMed 22085439 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2007, a primary completion of Apr 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2012, 3 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2008
First posted
Mar 5, 2008
Start
Dec 2007
Primary completionActual
Apr 2009
CompletionActual
Apr 2009
Results first posted
Oct 25, 2012
Last update
Oct 25, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 25, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00628862
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Mar 5, 2008
Start date
Dec 2007
Primary completion
Apr 2009
Completion
Apr 2009
Results posted
Oct 25, 2012
Last update
Oct 25, 2012

Study contacts

Lars-Goran Carlsson, MD
study director · AstraZeneca R&D Lund, Sweden
Miron A Bogdan, MD
principal investigator · Clinica Medic Or, Calea

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Formoterol

Start the discussion